1. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Issue 10337 (7th May 2022) Authors: Delany-Moretlwe, Sinead; Hughes, James P; Bock, Peter; Ouma, Samuel Gurrion; Hunidzarira, Portia; Kalonji, Dishiki; Kayange, Noel; Makhema, Joseph; Mandima, Patricia; Mathew, Carrie; Spooner, Elizabeth; Mpendo, Juliet; Mukwekwerere, Pamela; Mgodi, Nyaradzo; Ntege, Patricia Nahirya; Nair, Gonasagr... Journal: Lancet Issue: Volume 399:Issue 10337(2022) Page Start: 1779 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub‐Saharan Africa (HPTN 075). (1st October 2020) Authors: Sandfort, Theodorus GM; L Hamilton, Erica; Marais, Anita; Guo, Xu; Sugarman, Jeremy; Chen, Ying Q; Cummings, Vanessa; Dadabhai, Sufia; Dominguez, Karen; Panchia, Ravindre; Schnabel, David; Zulu, Fatima; Reynolds, Doerieyah; Radebe, Oscar; Mbeda, Calvin; Kamba, Dunker; Kanyemba, Brian; Ogendo, Art... Journal: Journal of the International AIDS Society Issue: Volume 23(2020)Supplement 6 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗